Andrew Tsai
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
17
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNS Marinus Pharmaceuticals | Downgrades: Hold | $5 → $0.5 | $0.33 | +50.33% | 1 | Oct 25, 2024 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $165 | $123.07 | +34.07% | 1 | Oct 21, 2024 | |
| RLMD Relmada Therapeutics | Upgrades: Buy | $3.5 → $13 | $3.42 | +280.12% | 2 | Sep 17, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $23.62 | +48.18% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $3.71 | +789.49% | 1 | Feb 27, 2024 | |
| VTGN Vistagen Therapeutics | Upgrades: Buy | $0.2 → $15 | $3.22 | +365.84% | 2 | Dec 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $1.21 | +148.96% | 1 | Mar 7, 2023 | |
| ATHA Athira Pharma | Downgrades: Hold | $32 → $3 | $0.64 | +368.82% | 2 | Jun 23, 2022 | |
| BEKE KE Holdings | Upgrades: Overweight | $23 → $16 | $22.17 | -27.83% | 1 | Mar 16, 2022 | |
| VIGL Vigil Neuroscience | Initiates: Buy | $20 | $3.87 | +416.80% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $70 | $86.17 | -18.77% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.08 | +2,400.00% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $41.71 | -44.86% | 1 | Jun 1, 2020 |
Marinus Pharmaceuticals
Oct 25, 2024
Downgrades: Hold
Price Target: $5 → $0.5
Current: $0.33
Upside: +50.33%
Sarepta Therapeutics
Oct 21, 2024
Initiates: Buy
Price Target: $165
Current: $123.07
Upside: +34.07%
Relmada Therapeutics
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $3.42
Upside: +280.12%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $23.62
Upside: +48.18%
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $3.71
Upside: +789.49%
Vistagen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $3.22
Upside: +365.84%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.21
Upside: +148.96%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $0.64
Upside: +368.82%
KE Holdings
Mar 16, 2022
Upgrades: Overweight
Price Target: $23 → $16
Current: $22.17
Upside: -27.83%
Vigil Neuroscience
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $3.87
Upside: +416.80%
Sep 20, 2021
Maintains: Buy
Price Target: $55 → $70
Current: $86.17
Upside: -18.77%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $1.08
Upside: +2,400.00%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $41.71
Upside: -44.86%